To evaluate by flow cytometry whether daratumumab and isatuximab compete for CD38 binding site, MM cell lines were labeled for 30 min with either daratumumab, biotinylated isatuximab, or a combination of both antibodies. Here, CD38 is linked to Miyoshi myopathy.